Iruxol Mono

Collagenase clostridium histolyticum, the active ingredient in Iruxol Mono, is a proteolytic enzyme presented as a topical preparation for cutaneous use. It facilitates debridement of chronic wounds, pressure ulcers, diabetic foot ulcers and removal of necrotic tissue.

GNH USA supplies Iruxol Mono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation, temperature‑controlled shipping where required, and dedicated technical support to ensure safe integration into wound‑care protocols.

Iruxol Mono, a proteolytic enzyme used in wound care, is indicated for the following conditions: - Chronic wounds: promotes enzymatic debridement of necrotic tissue to support healing. - Pressure ulcers: facilitates removal of devitalized tissue, preparing the ulcer for further treatment. - Diabetic foot ulcers: assists in clearing necrotic debris, aiding infection control and wound closure. - Necrotic tissue removal: provides targeted enzymatic breakdown of collagen‑rich necrotic tissue.

Topical application of Iruxol Mono may be associated with the following adverse reactions.

Common Side Effects: - Pain at application site - Redness - Swelling - Itching

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Deep tissue necrosis - Infection at treatment site

When using Iruxol Mono, clinicians should observe the following precautions to minimise risks. - Assess wound for infection before application: confirm absence of active infection or excessive exudate. - Avoid application on healthy tissue: limit use to necrotic areas only. - Do not use in patients with known hypersensitivity to collagenase: discontinue if reaction occurs. - Monitor for local irritation: discontinue if severe pain, erythema, or ulcer enlargement develops. - Store at room temperature: keep in original container, protect from moisture and light.

Iruxol Mono can interact with other agents; the following interactions should be considered.

Major Interactions (Avoid): - Concomitant use with other proteolytic enzymes: may increase tissue damage. - Use with systemic anticoagulants: may heighten bleeding risk at the wound site. - Combination with topical antibiotics containing bacitracin: can exacerbate local irritation.

Moderate Interactions (Monitor Closely): - Co‑application with silver‑containing dressings: may reduce enzyme activity. - Use alongside immunosuppressants: could affect wound healing dynamics. - Simultaneous use of other topical agents: may alter absorption or efficacy.